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OBJECTIVE—Peripheral blood CD34
 cells from diabetic pa-
tients demonstrate reduced vascular reparative function due to
decreased proliferation and diminished migratory prowess,
largely resulting from decreased nitric oxide (NO) bioavailability.
The level of TGF-, a key factor that modulates stem cell
quiescence, is increased in the serum of type 2 diabetic patients.
We asked whether transient TGF-1 inhibition in CD34
 cells
would improve their reparative ability.
RESEARCH DESIGN AND METHODS—To inhibit TGF-1
protein expression, CD34
 cells were treated ex vivo with antisense
phosphorodiamidate morpholino oligomers (TGF-1-PMOs) and
analyzed for cell surface CXCR4 expression, cell survival in the
absence of added growth factors, SDF-1-induced migration, NO
release, and in vivo retinal vascular reparative ability.
RESULTS—TGF-1-PMO treatment of diabetic CD34
 cells
resulted in increased expression of CXCR4, enhanced survival in
the absence of growth factors, and increased migration and NO
release as compared with cells treated with control PMO. Using
a retinal ischemia reperfusion injury model in mice, we observed
that recruitment of diabetic CD34
 cells to injured acellular
retinal capillaries was greater after TGF-1-PMO treatment com-
pared with control PMO–treated cells.
CONCLUSIONS—Transient inhibition of TGF-1 may represent a
promising therapeutic strategy for restoring the reparative capacity
of dysfunctional diabetic CD34
 cells. Diabetes 59:2010–2019,
2010
B
one marrow derived progenitor cells (BMPCs)
support vascular repair postnatally by direct
integration into blood vessels and by the release
of paracrine factors such as vascular endothelial
cell growth factor, matrix metalloproteases, and angiopoi-
etins to the neovessels (1,2). BMPCs possess dramatic
ability to revascularize areas within 6–12 h after the injury
(3), accounting for total 1–12% of the endothelial cells
present in blood vessels (4). Lineage negative (lin
) cells
from mice that express the cell surface antigens Sca-1
(Ly-6A/E) and c-kit can develop into endothelium, as can
human lin
 cells expressing surface CD34 (1,5). Treatment
with CD34
 cells presents an important therapeutic option
for revascularization of ischemic vascular areas (6) and
has been successful in numerous clinical trials (7,8).
However, diabetes signiﬁcantly impairs the vasorepara-
tive ability of CD34
 cells. Diabetic patients with periph-
eral vascular disease have decreased levels of CD34
 cells
and suffer poor vessel growth in response to ischemia (9);
this defect is linked to reduced precursor cell function
(10). The widespread vasodegeneration seen in diabetic
retinopathy may be attributed to the inability of BMPCs to
compensate for the increased endothelial injury associ-
ated with diabetes. In particular, the diabetic BMPCs are
unable to repair retinal vasculature (11); thus, the total
rate of retinal cell loss greatly exceeds the reparative
function of these cells. We showed that diabetic CD34

cells fail to revascularize areas of retinal vascular injury
(11) likely due to reduced migration. Diabetic peripheral
neuropathy further hampers repair due to defects of
circadian release of BMPCs from the bone marrow, creat-
ing an imbalance between the demand and supply of
BMPCs during the vasodegenerative stage of diabetic
retinopathy (12). Pharmacological manipulation of dia-
betic CD34
 cells (13) can serve as an important thera-
peutic strategy for their use as autologous cell therapy to
facilitate vascular repair.
Transforming growth factor-1 (TGF-1) is a pleiotropic
factor that regulates the balance between proliferation,
differentiation, and quiescence of hematopoietic stem cells
(HSCs), both as an extracellular and intracellular ligand
(14,15). TGF-1 is elevated in the serum of diabetic
patients and possibly intracellularly in CD34
 cells (16).
Enhanced levels of endogenous TGF-1 have been re-
ported in peripheral blood mononuclear cells of patients
with diabetic nephropathy (17), and its increase provides a
novel mechanism of cellular injury related to elevated
glucose levels (18). Increased levels of TGF-1 induce
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antibodies, we showed that transiently inhibiting TGF-1
in murine HSCs promoted survival of these cells in the
absence of growth factors (20).
In this study, we investigated the effect of transient
inhibition of endogenous TGF-1 in peripheral blood
diabetic CD34
 cells using ex vivo treatment with phos-
phorodiamidate morpholino oligomers (PMOs). PMOs act
by stearic inhibition of protein synthesis by high afﬁnity
binding to 14–15 contiguous bases. PMOs are highly stable
both intra- and extracellularly but are degraded after
binding with a half-life of 2–4 days in cells (21). We
report here that transient inhibition of TGF-1 using
TGF-1-PMO may represent a promising therapeutic strat-
egy for restoring vascular reparative function in dysfunc-
tional diabetic CD34
 cells.
RESEARCH DESIGN AND METHODS
All animal studies were approved by the institutional animal care and use
committee, and studies were conducted in accordance with The Guiding
Principles in the Care and Use of Animals (National Institute of Health) as well
as the Association of Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research.
Isolation of murine HSCs. HSCs were harvested from the bone marrow
obtained from femurs and tibiae of C57BL/6-Tg (UBC-GFP) 30Scha/J mice
homozygous for green ﬂuorescent protein (GFP) antibodies. Fluorescently
labeled c-kit (CD117) and Sca-1 (BD PharMingen, San Diego, CA) were used
to enrich HSCs from mononuclear cell fractions using a BD cell sorter (FACS
Calibur, BD Bioscience, San Jose, CA). We have previously shown that this
technique yields a 95% pure hemangioblast cell/HSC population (5).
Isolation of long-term repopulating HSCs. The detailed protocol for the
isolation of long-term repopulating HSCs (LTR-HSCs) was previously de-
scribed (22). Brieﬂy, a dose response of LTR-HSCs (30–1,000 cells) pretreated
for 1 h with anti-TGF-1 neutralizing antibody (clone 1D11.16) or IgG1K
isotype control antibody, both at 20 g/ml (R & D Systems, Minneapolis, MN),
were transplanted intravenously into lethally irradiated mice, and survival was
examined over time.
Acute vascular injury: ischemia reperfusion injury model. Acute vascu-
lar injury was induced in mice using the ischemia reperfusion model, as
detailed in an online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db10-0287/DC1. Brieﬂy, the anterior chamber of the eye was then
subjected to2ho fincreased hydrostatic pressure, resulting in retinal
ischemia. This model results in the generation of acellular capillaries similar
to what is observed in longstanding diabetic retinopathy but occurs after 7
days of injury (23). At this time, the animals received injections of isolated
human CD34
 cells pretreated with either TGF-1-PMO or control PMO into
their vitreous.
TGF-1 inhibition using PMO. TGF-1-PMOs or control PMOs (AVI-
Biopharma, Portland, OR) were synthesized, lyophilized, dissolved in sterile
distilled water, and serially diluted. CD34
 cells were incubated for 16 h at
37°C in Iscove’s modiﬁed Dulbecco’s medium containing 10% FBS, 10%
selected horse serum, and 40 g/ml PMO. The detailed protocol for PMO
treatment is described in an online appendix.
Endogenous TGF-1 expression using ﬂow cytometry. Lin
Sca-1
 cells
(described above) were treated with anti-TGF-1 antibodies or TGF-1-PMO.
Endogenous expression of TGF-1 was then studied after ﬁxation and
permeabilization using phycoethrin-labeled TGF-1 antibodies (IQ Products,
Groningen, Holland) and analyzed by ﬂow cytometry (FACS Vantage DiVa I
ﬂow cytometer, San Jose, CA). Anti-actin antibodies (BD PharMingen) served
as control.
Patient selection. Peripheral blood samples (50 ml) were collected from
type 2 diabetic patients and healthy age-matched volunteers. The study was
approved by the University of Florida Institutional Review Board. All partic-
ipants gave written informed consent to participate. Criteria for inclusion and
exclusion of participants are provided in an online appendix, and detailed
patient characteristic are described in supplementary Tables 1 and 2 (also
available in an online appendix).
Isolation of human CD34
 cells. Mononuclear cells were isolated from
peripheral blood using Lymphoprep and then subjected to magnetic selection
of lin
 cells yielding lin
 cells (Stem Cell Technologies, Vancouver, BC,
Canada), which were then incubated with anti-CD34-phycoethrin and anti-
CD45-phycoethrin-Cy7 (BD PharMingen) and other select antibodies. Lin

CD34
 CD45
mid cells were clearly resolved from lymphocytes and other
myeloid cells using a FACS Vantage DiVa ﬂow cytometer. CD34
 cells
enriched by Miltenyi positive selection from human cord blood and bone
marrow obtained from AllCells (Emeryville, CA) and were 95% pure as
assessed by ﬂuorescence-activated cell sorter (FACS) analysis. Viability was
determined by 7AAD exclusion and was routinely 95% after washings
(detailed protocol in an online appendix).
CD34
 survival in the absence of added growth factors. Lin

CD34
CD45
mid cells from cord blood or peripheral blood were directly sorted
into 96-well plates (10  3 cells per well) containing plain medium, control
PMO, or TGF-1-PMO. Cell viability and proliferation were assessed daily
using direct light microscopy (200), both before growth factors and after
their addition. Recombinant hematopoietic growth factor cocktail was added
on day 5 to each well that contained human TPO (20 ng/ml), stem cell factor
(50 ng/ml), IL-3 (50 ng/ml), and IL-6 (20 ng/ml) (PeproTech, NJ). Cells were
scored that survived after the initial 5-day period in the absence of growth
factors.
Migration assay. Cell migration after overnight inhibition with TGF-1-PMOs
or control PMOs was analyzed using a modiﬁed Boyden chamber assay as
described previously (24).
CXCR4 expression on CD34
 cells. At T 	 0 and after treatment with
TGF-1-PMO for 16 h, healthy or diabetic CD34
 cells were incubated with
CD34, CD45, and CXCR4 antibodies (BD Bisociences) to analyze CXCR4
expression using FACS (BD Bioscience).
Determination of NO production by 4-amino-5-methylamino-2-diﬂu-
oroﬂuorescein ﬂuorescence imaging. NO production was quantiﬁed in
peripheral blood CD34
 cells using NO-sensitive 4-amino-5-methylamino-2-
diﬂuoroﬂuorescein (DAF-FM) ﬂuorescence, as described previously (25).
Statistical analyses. Data are presented as mean values  SEM. Statistical
analyses were performed using GraphPad InStat 3.0 (GraphPad Software, San
Diego, CA). Statistical differences in the mean were assessed using one-way
ANOVA followed by Tukey Carmer post hoc test or unpaired t test.
RESULTS
TGF-1 inhibition in vitro promotes engraftment of
murine LTR-HSCs. To study the effect of TGF-1 inhibi-
tion on survival and engraftment of LTR-HSCs, mice were
lethally irradiated with 950 rads and anti-TGF-1 anti-
body–treated LTR-HSCs were transplanted. As shown in
Fig. 1A, isotype antibody-treated LTR-HSC did not mediate
survival of lethally irradiated mice over a range of 30–500
cells per mouse, and even at 1,000 LTR-HSC per mouse,
the six-month survival was only 10%. In striking contrast,
anti-TGF-1 treatment for 1 h before transplant resulted in
survival of 70% of mice at 60 cells per mouse. However,
if 250 LTR-HSC were treated with anti-TGF-1 antibody
before transplant, essentially 100% of mice survived for 6
months post transplant.
Neutralizing antibody targets only cell surface TGF-1.
We also wanted to evaluate the pharmacological effect of
both neutralization of cell surface TGF-1 and intracellu-
lar TGF-1 and used PMOs. FACS analysis on murine lin

Sca1
 c-kit
 cells treated with either TGF-1-PMO or
TGF-1 neutralizing antibody resulted in speciﬁc inhibi-
tion of endogenous TGF-1 (Fig. 1B). A functional assay
that we used is survival of enriched progenitor cells in the
absence of growth factors. Both murine LTR-HSC and
human CD34
 cells exhibit a rapid death curve in the
absence of stem cell growth factors. We observed that
inhibition of endogenous TGF-1 in LTR-HSC resulted in
prolonged survival of the cells even in single cell per well
cultures (data not shown). Human CD34
 cells also sur-
vive in the absence of growth factors if TGF-1-PMO was
present (supplementary Fig. 1, available in an online
appendix). Unexpectedly, human CD34
 cells did not
survive in the absence of growth factors when TGF-1
neutralizing antibody was present (in contrast to murine
LTR-HSC) (supplementary Fig. 1) but did so when cul-
tured with TGF-1-PMO. Human CD34
 cells not only
proliferated in response to the added growth factors after
5 days but generated large numbers of progeny during the
subsequent 7-day growth period with growth factors
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TGF-1 neutralizing antibody did not promote survival of
CD34
 cells in the absence of growth factors, nor did they
respond to added growth factors at day 5. At this point, we
chose to exclusively use TGF-1-PMO and not TGF-1
neutralizing antibody for subsequent studies with human
cells.
The PMOs used in these studies were 18–21 oligonucle-
otides in length, which showed excellent cellular uptake
without the aid of any transfection reagent or peptide
conjugation. To further establish kinetics PMO uptake by
CD34
 cells, ﬂuorescein isothiocyanate (FITC)-conjugated
PMO were developed (FITC-PMO kindly provided by Pat
Iversen, AVI-Biopharma). FITC-PMOs were rapidly taken
up by peripheral blood CD34
 cells in an exponential
manner; at 40 g/ml FITC-PMO, a plateau was observed
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FIG. 1. Inhibition of endogenous TGF-1 in murine LTR-HSC accelerates engraftment and enhances repopulating efﬁciency. A: When low numbers
of highly enriched bone marrow LTR-HSCs (see Methods) were treated with anti-TGF-1 neutralizing antibody just before transplant into
lethally irradiated mice (950 rads) without the support of helper bone marrow, a large proportion of mice survived irradiation death. The
proportion of mice that survived for six months after transplantation is shown. The datum is expressed as mean survival of 10–20 mice/group.
B: Both anti-TGF-1 PMO and TGF-1 neutralizing cell surface antibodies inhibit endogenous expression of TGF-1 in primitive hematopoietic
cells (lin
 Sca-1
-cells). Enriched bone marrow cells were treated with anti-TGF-1 PMOs or antibodies overnight, cells were ﬁxed and
permeabilized, and phycoethrin-labeled TGF-1 antibodies were used to detect endogenous TGF-1. Anti-actin antibodies served as the
permeabilization control. Flow cytometry dot plots were divided into four quadrants showing TGF-1 expression on the y-axis and actin
expression on the x-axis. Values in the upper right quadrant of each individual plot indicate the percent of TGF-1 expressing cells. The bottom
two plots show that use of either TGF-1 blocking antibody or TGF-1-PMO reduced the percentage of cells expressing TGF-1. For the TGF-1
blocking antibody studies, the percentage of cells expressing TGF- 1 fell from 90.1 to 23.8%, while for the TGF-1-PMO studies, the percentage
fell from 51.2 to 14.6% (n  10–20 mice/group). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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tion of 160 g/ml, saturation occurred within 1–3 h (sup-
plementary Fig. 2, available in an online appendix).
TGF-1 inhibition in murine HSCs increases homing
to areas of ocular injury. We pretreated murine HSCs
(lin
c-kit
Sca1
) with TGF-1 PMO or control PMO and
tested cell homing to areas of laser injury. As shown in
supplementary Fig. 3 (available in an online appendix),
pretreatment with TGF-1-PMO substantially increased
the number of GFP
 HSCs that were recruited to the sites
of laser rupture of Bruch’s membrane compared with
control PMO–treated cells (P 
 0.05).
Inhibition of endogenous TGF-1 in CD34
 cells
increases vascular repair in the retinal ischemia
reperfusion injury model. We next examined the repar-
ative function of diabetic CD34
 cells after pretreatment
with TGF-1-PMO or control PMO in the ischemia reper-
fusion model, which recapitulates key aspects of the
vasodegenerate phase (acellular capillaries) of diabetic
retinopathy. Analysis of retinal ﬂat mounts showed that
pretreatment of both diabetic and healthy CD34
 cells
with TGF-1-PMO increased homing to areas of retinal
injury to a greater degree than control PMO (Fig. 2A).
Diabetic CD34
 cells showed a 2.2-fold lower colocaliza-
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FIG. 2. TGF-1-PMO–treated HSCs integrate into degenerating capillaries in the ischemia reperfusion–damaged retina. A: Representative
immunoﬂuorescence images showing incorporation of intravitreally injected CD34
 cells (labeled green) into the retinal ischemic vasculature
(red). Note that TGF-1-PMO–treated CD34
 cells show a substantial increase in incorporation into the vasculature. B: Morphometric
quantiﬁcation of blood vessel–colocalized CD34
 cells expressed as the percentage of the vascular area (n  5 mice each group). Cont  control.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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 cells (Fig.
2B). Pretreatment of healthy CD34
 cells with TGF-1-
PMO resulted in a 2.51-fold (P 
 0.01) increase in the
numbers of CD34
 cells homing to injured vessels. On the
other hand, treatment of diabetic CD34
 cells with TGF-
1-PMO produced a robust reparative response (P 
 0.01),
as seen by a 5.4-fold (P 
 0.01) increase in numbers of
CD34
 cells colocalized with vessels supporting the re-
stored ability of these cells to home to acellular capillaries
(Fig. 2B).
Inhibition of TGF-1 using PMO increases survival of
diabetic CD34
 cells. Our animal studies showed that
inhibition of TGF-1 improved homing to areas of injury,
the critical ﬁrst step in repair. To evaluate the mechanism
responsible for the improvement in CD34
 cell homing
after transient inhibition of endogenous TGF-1, we ﬁrst
tested the impact of PMO treatment on survival of human
CD34
 cells. For these studies, we used CD34
 cells from
sources that would be typically used for human revascu-
larization trials, such as cord blood, bone marrow, and
peripheral blood. Cord blood and bone marrow CD34

cells were cultured in medium with or without PMOs for 5
days. In the absence of growth factors, 95% of human lin

CD34
 cells died after 2–3 days, even though they were
cultured in a rich medium (Iscove’s modiﬁed Dulbecco’s
medium with 10% FBS and 10% horse serum). In contrast,
TGF-1-PMO–treated normal cord blood and bone mar-
row cells survived (P 
 0.05) in the absence of growth
factors and continued their growth over the course of an
additional 7 days (Fig. 3A). Next, peripheral blood CD34

cells from diabetic subjects and age- and sex-matched
control subjects were tested. As observed for cord blood
and bone marrow CD34
 cells, the addition of growth
factors elicited greater proliferation in TGF-1-PMO–
treated peripheral blood cells than in control PMO-treated
cells (P 
 0.05) (Fig. 3B).
TGF1-1-PMO improved migration of diabetic CD34

cells to SDF-1 and increased CXCR4 expression.
Inhibition of endogenous TGF-1 expression enhanced
migration of both diabetic (P 
 0.05 vs. control PMO) and
healthy cells (P 
 0.01 vs. control PMO) (Fig. 4). To
understand the mechanisms involved in this enhanced
migratory function of CD34
 cells, we analyzed expres-
sion of the SDF-1 receptor, CXCR4. Enriched CD34
 cells
were gated for the CD34
 CD45
mid population (Fig. 5A),
and CXCR4 expression was analyzed (Fig. 5B). We found
that CXCR4 surface expression was greater in TGF-1-
PMO–treated diabetic cells than in control PMO-treated
cells (P 	 0.004). A similar trend was observed in healthy
cells; however, it did not achieve statistical signiﬁcance.
Inhibition of endogenous TGF-1 increases SDF-1–
induced NO generation in diabetic CD34
 cells. Bio-
available NO is reduced in diabetic progenitors, and this
contributes to the migratory dysfunction observed in these
cells (13,26). Because inhibition of TGF-1 in healthy and
diabetic CD34
 cells increased migration and homing in
both animal models, we asked whether this effect was
coupled to enhanced NO generation. In healthy CD34

cells, SDF-1 (100 nmol/l) increased NO generation by 45 
4% (Fig. 6). The signal transduction pathway involved in
SDF-1–induced NO release in CD34
 cells has not been
elucidated. To delineate this pathway, we tested different
pharmacological inhibitors. SDF-1–induced NO release
was signiﬁcantly decreased when cells were pretreated
with one of the following: 10 mol/l AMD3100, a speciﬁc
nonpeptide CXCR4 antagonist (3  2%, P 
 0.001); 100
ng/ml pertussis toxin, a Gi protein inhibitor (20  9%, P 

0.01); 20 mol/l LY294002, a phosphoinositide 3-kinase
(PI3K) inhibitor (12  3%, P 
 0.001); or 30 mol/l
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 0.01) (Fig. 6).
These results suggest that, in CD34
 cells, SDF-1–induced
NO release involves the CXCR4/Gi-protein/PI3K/Akt
pathway.
Next, we determined whether pretreatment with control
or TGF-1-PMO inﬂuenced NO release in these cells. We
found that SDF-1 elicited a comparable degree of NO
release in healthy, peripheral blood CD34
 cells that had
been pretreated with either control PMO (60  5%) or
TGF-1-PMO (54  4%) (Fig. 7A, B). In contrast, SDF-1–
induced marked NO generation in diabetic CD34
 cells
treated with TGF-1-PMO (69  7%, P 
 0.0001) but not in
cells treated with control PMO (9.2%) (Fig. 7A, B). This
ability of TGF-1-PMO to restore NO release in diabetic
CD34
 cells was diminished by the selective CXCR4
inhibitor, AMD3100 (28  2%, P 
 0.01), supporting that
this effect was mediated by CXCR4 activation.
DISCUSSION
Therapeutic revascularization with endothelial progenitor
cells holds promise as a treatment modality to prevent
tissue damage and restore blood ﬂow in individuals such
as diabetic subjects who are not ideal candidates for
standard revascularization procedures because of their
small vessel disease. However, while cell therapy is
needed in diabetic patients, this approach has limited
utility because of endothelial progenitor cell dysfunction
(27,28). Speciﬁcally, endothelial progenitors isolated from
diabetic individuals demonstrate reduced proliferation,
migration, and differentiation into endothelial cells. Expo-
sure to high concentrations of glucose reduces endothelial
nitric oxide synthase (eNOS) expression in these cells.
HIF-1 modiﬁcation by methylglyoxal, a consequence of
increased reactive oxygen species formed during high
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db/db mice show reduced expression of eNOS and phos-
pho-eNOS (29). Consistent with this ﬁnding, we have
shown that human diabetic CD34
 cells have reduced NO
bioavailability, which is associated with decreased migration
that can be restored through exposure to NO donors (13).
In this study, we tested whether the reparative function
of diabetic progenitors could be enhanced through inhibi-
tion of TGF-1, a novel approach that we hypothesized
could correct multiple functional defects in these cells. We
found that pretreating CD34
 progenitors with TGF-1-
PMO enhanced proliferation and migration in vitro as well
as homing in two preclinical in vivo models of injury.
Endogenous TGF-1 has been shown to be a primary
factor maintaining HSCs in G0/G1. However, exogenous
TGF-1 (in plasma and tissue), SDF-1/CXCR4 signaling,
and circulating growth factors could also regulate HSC cell
cycle status. Although the majority of TGF-1 is expressed
as a latent, inactive form, HSCs and BMPCs express
transglutaminase and other proteolytic enzymes that can
activate endogenous TGF-1 (S.H.B., unpublished data).
Accordingly, active intracellular TGF-1 has been identi-
ﬁed in HSCs and endothelial progenitors (30). HSC quies-
cence, division, and daughter cell fate decisions have been
shown to be mediated by the TGF-1/hematopoietic
growth factor axis (22,31).
Previously, it has been reported that inhibition of
TGF-1 induces G0-to-G1 transition (32). Here we ﬁnd that
it promotes cell migration and proliferation and improves
homing of CD34
 cells to the vasculature. If intracellular
or extracellular TGF-1 is withdrawn from CD34
 cells in
the presence of optimal hematopoietic growth factors,
then G0 cells rapidly shift to G1 and the G2/M/S interface.
TGF-1 inhibition drives CD34
cells into G1 (33) and has
been shown to increase the engraftment potential of HSCs
(34). In contrast to TGF-1 inhibition, withdrawal of
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 cell death,
some of which is mediated by TGF-1 (35).
Here we show that if TGF-1 is inhibited intracellularly
in the absence of hematopoietic growth factors, human
CD34
 cells can survive for 1 week ex vivo. In vivo we
observe an enhanced reparative response that is likely due
not only to increased migration of the TGF-1-PMO–
treated human CD34
 cells but also to increased prolifer-
ation at the site of vascular injury. Similar to engraftment
into the bone marrow of LTR-HSC after TGF-1-PMO
treatment, we observed correction of defective homing in
the diabetic CD34
 cells treated with TGF-1-PMO. To
better understand the mechanisms of this beneﬁcial effect,
we ﬁrst focused on the SDF-1/CXCR4 pathway that has
been show to be central to mediating tissue repair after
injury. SDF-1 is highly expressed by ischemic tissue and
can also increase progenitor cell homing back to the bone
marrow (36,37). SDF-1 plays an important role in vascular
development (38), and ablation of the SDF-1/CXCR4 gene
in mice produces defects in blood vessel formation. As
shown in Fig. 1A, anti-TGF-–treated LTR-HSC demonstrates
increased homing to the bone marrow, and as shown in Fig.
2 and supplementary Fig. 3, anti-TGF-–treated cells migrate
better to injured tissue. This can be due to increased CXCR-4
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tial. Our results revealed that the migration of human CD34

cells to SDF-1 was reduced in diabetic cells and that this
migratory defect was corrected by endogenous TGF-1 inhi-
bition, suggesting that efﬁcient signal transduction of the
SDF-1/CXCR4 pathway was restored.
To further understand the inﬂuence of TGF-1 inhibi-
tion on this pathway, we evaluated NO release in response
to SDF-1 and used different pharmacological inhibitors to
delineate the involvement of CXCR-4 receptor signaling
pathway in SDF-1–induced NO release. Importantly, our
studies also indicate that SDF-1–induced NO release oc-
curred via activation of CXCR-4, and this involved Gi
protein, PI3K and subsequent Akt activation. Akt activates
eNOS by phosphorylation at Ser
1177, resulting in NO pro-
duction (39,40) Our ﬁndings are consistent with earlier
studies showing that SDF-1–induced chemotaxis of T
lymphocytes involves Gi protein-coupled PI3K activation
and Akt phosphorylation (41,42).
We found that healthy CD34
 cells demonstrated robust
NO release in response to SDF-1 and TGF-1 inhibition did
not increase NO release further. This suggests that
CXCR-4 activation required for NO release in response to
SDF-1 was already maximal in the nondiabetic cells,
before TGF-1 inhibition using PMOs. In contrast, TGF-1
inhibition in diabetic CD34
 cells corrected defective NO
release in response to SDF-1, in part by signiﬁcantly
increasing the expression of CXCR-4 on the diabetic cells,
which was not the case for the nondiabetic cells (Fig. 5B).
This implies that, in healthy nondiabetic CD34
 cells,
activation of CXCR-4 triggers NO-independent signaling
pathways, such as tyrosine phosphorylation of Wiskott-
Aldrich syndrome protein (WASp). WASp is a critical
regulator of actin cytoskeleton remodeling after CXCR-4
activation. SDF-1 exposure results in Cdc42 activation and
WASp tyrosine phosphorylation as well as in WASp asso-
ciation with Fyn and Pyk-2 tyrosine kinases (43). Here, we
observed that cells were recruited to areas of vascular
injury in two distinct but complementary injury models.
Systemic administration of TGF-1-PMO–treated murine
LTR-HSC’s increased the homing of these cells to sites of
neovascularization (supplementary Fig. 3) and intravitreal
administration of TGF-1-PMO–treated CD34
 cells en-
hanced homing to injured retinal vessels (Fig. 2). Both the
laser injury model and the ischemia reperfusion model
result in release of angiogenic growth factors (44). We
have previously shown that laser injury alone is sufﬁcient
to induce stem cell recruitment as early as 1 week after
injury (45). In this model, SDF-1 antibodies reduce the
recruitment of HSCs to the choroidal neovascularization
lesion, suggesting that SDF-1/CXCR-4 participates in the
recruitment of cells to sites of laser injury (46). Our
current study suggests that treatment of the murine HSCs
and human CD34
cells with TGF-1-PMO increases their
homing to areas of injury by enhancing their migratory
potential. This is likely due to increased surface expres-
sion of CXCR-4 mediated by TGF-1-PMO exposure. Acti-
vation of CXCR-4 generates NO, which is critical to CD34

cell migration (13,47).
Retinal and subretinal ischemia contributes to visual
impairment and blindness in diseases as diverse as reti-
nopathy of prematurity, diabetic retinopathy, and age-
related macular degeneration. The ischemia reperfusion
model mimics many aspects of the pathophysiology of
retinal ischemia and leads to the development of acellular
capillaries. We have previously shown that, in this model,
healthy CD34
/endothelial precursors reendothelialize
ischemic capillaries; however, diabetic CD34
/endothelial
precursor cells do not (11). In the present study, inhibition
of TGF-1 enhanced the recruitment of diabetic as well as
healthy CD34
 cells to sites of retinal injury and corrected
this defect in diabetic CD34
 cells.
In conclusion, our studies show that transient inhibition
of TGF-1 in CD34
 cells ex vivo enhances repair after
vascular damage. This ﬁnding may have a profound impact
on disease states associated with vascular dysfunction
such as ischemic heart disease and diabetic vascular
complications. While an attempt is being made to replace
traditional approaches for alleviating tissue ischemia (e.g.,
stents, angioplasty, or vessel grafts) with cell therapy,
autologous cellular therapy has not been feasible in dia-
betic patients because of dysfunctional cells. Transient
inhibition of TGF-1 may represent a promising therapeu-
tic strategy for restoring vascular reparative function in
diabetic CD34
 cells and may increase the likelihood of
successful cellular therapy in diabetic individuals.
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